Company
Bayer
Bayer has 60 drugs tracked on RxWires: 8 post-market, 8 approved, 11 in Phase 3, 18 in Phase 2, 3 in Phase 1/2, 9 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Tacrolimus | Post-Market | Diabetes Mellitus |
| rFVIII-FS (Kogenate FS, BAY14-2222) 70 IU/kg, dosing once per week | Post-Market | Hemophilia A |
| Aflibercept (BAY86-5321, Eylea) | Post-Market | Diabetic Macular Edema |
| Darolutamide (Nubeqa, BAY1841788) | Post-Market | Non-metastatic Castration-resistant Prostate Cancer |
| Darolutamide combined with 177Lu-PSMA-617 | Post-Market | Prostate Cancer |
| Diagnostic procedures | Post-Market | Anterior Ischemic Optic Neuropathy |
| levonorgestrel IUS | Post-Market | Epilepsy |
| Long Acting Reversible Contraception (LARC) | Post-Market | Contraception |
| SKYLA | Approved | |
| BILTRICIDE | Approved | |
| MYCELEX-7 | Approved | |
| MAGNEVIST | Approved | |
| CORT-DOME | Approved | |
| CHLOR-TRIMETON | Approved | |
| KERENDIA | Approved | |
| AVELOX | Approved | |
| Levitra (Vardenafil, BAY38-9456) | Phase 3 | Erectile Dysfunction |
| Sevabertinib | Phase 3 | Advanced Non-small Cell Lung Cancer, HER2 Mutation |
| Angeliq (Drospirenone/17ß-estradiol, BAY86-4891) | Phase 3 | Hypertension |
| Nexavar (Sorafenib, BAY43-9006) | Phase 3 | Carcinoma, Hepatocellular |
| Vardenafil ODT (STAXYN, BAY38-9456) | Phase 3 | Erectile Dysfunction |
| Lanthanum carbonate (BAY77-1931) | Phase 3 | Hyperphosphatemia |
| EV/DNG (Qlaira, BAY86-5027, SH T00658K) | Phase 3 | Contraception |
| Campath-1H /ATG | Phase 3 | Acute Myeloid Leukemia |
| Gadobutrol (Gadovist, BAY86-4875) | Phase 3 | Magnetic Resonance Imaging |
| SARS-CoV-2 mRNA Vaccine (CVnCoV) | Phase 3 | SARS-CoV-2 Infection |
| BAY1841788 / darolutamide (ODM-201) | Phase 3 | Metastatic Hormone-sensitive Prostate Cancer |
| Pentostatin | Phase 2 | Lymphoma |
| BAY2927088 | Phase 2 | Advanced Solid Tumors |
| BAY 3401016 | Phase 2 | Alport Syndrome |
| BAY2757556 (Larotrectinib, Vitrakvi) | Phase 2 | Solid Tumors Harboring NTRK Fusion |
| 90Y Ibritumomab tiuxetan | Phase 2 | Follicular Lymphoma |
| Campath-1H | Phase 2 | Chronic Lymphocytic Leukemia |
| Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin) | Phase 2 | Metastatic Colorectal Cancer |
| Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894) | Phase 2 | Melanoma |
| Regorafenib in combination with Tislelizumab | Phase 2 | Anal Squamous Cell Carcinoma |
| Azacytidine | Phase 2 | Leukemia |
| Xarelto (Rivaroxaban, BAY59-7939) | Phase 2 | Venous Thromboembolism |
| Tamoxifen | Phase 2 | Ovarian Carcinoma |
| Cinaciguat (BAY58-2667) | Phase 2 | Heart Failure |
| Niclosamide + Camostat | Phase 2 | Covid19 |
| Testosterone Cypionate | Phase 2 | Prostate Cancer |
| Temozolomide | Phase 2 | Glioblastoma |
| Ciprofloxacin (Cipro, BAYQ3939) | Phase 2 | Bronchiectasis |
| Radium-223 dichloride (Xofigo, BAY88-8223) | Phase 2 | Breast Neoplasms |
| BAY 3713372 | Phase 1/2 | MTAP-deleted Solid Tumors |
| Ra-223 Dichloride | Phase 1/2 | Sarcoma |
| Rituximab | Phase 1/2 | Non-Hodgkins Lymphoma |
| Rivaroxaban (Xarelto, BAY59-7939) | Phase 1 | Thromboembolic Disorders |
| Copanlisib (Aliqopa, BAY80-6946) | Phase 1 | Lymphoma, Non-Hodgkin |
| BAY2328065 | Phase 1 | Endometriosis |
| BAY1834845 | Phase 1 | Healthy Volunteers |
| Nifurtimox (BAYa2502) (4 x 30 mg tablet) | Phase 1 | Chagas Disease |
| Elinzanetant (BAY3427080) | Phase 1 | Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men |
| BAY1817080 | Phase 1 | Endometriosis Related Pain |
| Niraparib | Phase 1 | Prostate Carcinoma Metastatic to the Bone |
| BAY3389934 | Phase 1 | Sepsis |
| BAY987521 | Not Applicable | Sunscreening Agents |
| Mirena | Not Applicable | Menopausal and Other Perimenopausal Disorders |
| SPF 50 Y65 110 (BAY 987516) | Not Applicable | Sunscreening Agents |
Latest
- SKYLA: patent 11628088 expires 2027-02-07
- Darolutamide moved to Phase 3
- Boxed warning added: LEVONORGESTREL
Follow Bayer on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.